COSCIENS Biopharma Inc. (CSCI) — Cash Flow-to-Debt Ratio
COSCIENS Biopharma Inc. (CSCI) has a Cash Flow-to-Debt Ratio of -0.22x as of June 2025, meaning its operating cash flow of $-4.45 Million could theoretically repay 0% of its total liabilities ($20.46 Million) in one year. See COSCIENS Biopharma Inc. free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
COSCIENS Biopharma Inc. Cash Flow-to-Debt Ratio (1996–2024)
Historical debt coverage capacity for COSCIENS Biopharma Inc. across 29 annual periods. Also explore COSCIENS Biopharma Inc. (CSCI) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for COSCIENS Biopharma Inc. (1996–2024)
Year-by-year debt coverage analysis for COSCIENS Biopharma Inc.. For market capitalisation and broader financial context, see COSCIENS Biopharma Inc. market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.66x | $-14.57 Million | $21.91 Million | ▲ +30.2% |
| 2023 | -0.95x | $-2.58 Million | $2.71 Million | ▼ -173.1% |
| 2022 | 1.30x | $5.23 Million | $4.01 Million | ▲ +23.7% |
| 2021 | 1.05x | $2.75 Million | $2.61 Million | ▲ +16.3% |
| 2020 | 0.91x | $3.49 Million | $3.85 Million | ▲ +409.3% |
| 2019 | 0.18x | $675.29K | $3.79 Million | ▲ +117.7% |
| 2018 | -1.01x | $-1.56 Million | $1.55 Million | ▼ -436.6% |
| 2017 | 0.30x | $1.25 Million | $4.19 Million | ▼ -75.6% |
| 2016 | 1.22x | $3.63 Million | $2.97 Million | ▲ +140.5% |
| 2015 | 0.51x | $2.87 Million | $5.64 Million | ▲ +33.3% |
| 2014 | 0.38x | $1.84 Million | $4.82 Million | ▲ +278.1% |
| 2013 | 0.10x | $460.21K | $4.56 Million | ▲ +433.6% |
| 2012 | -0.03x | $-117.82K | $3.89 Million | ▼ -113.7% |
| 2011 | 0.22x | $791.62K | $3.58 Million | ▲ +60.3% |
| 2010 | 0.14x | $479.50K | $3.47 Million | ▲ +159.0% |
| 2009 | -0.23x | $-925.47K | $3.96 Million | ▼ -10.3% |
| 2008 | -0.21x | $-909.41K | $4.29 Million | ▲ +40.8% |
| 2007 | -0.36x | $-1.10 Million | $3.06 Million | ▼ -484.3% |
| 2006 | 0.09x | $140.59K | $1.51 Million | ▲ +142.6% |
| 2005 | -0.22x | $-368.84K | $1.69 Million | ▼ -280.8% |
| 2004 | -0.06x | $-76.65K | $1.33 Million | ▼ -171.1% |
| 2003 | 0.08x | $54.42K | $673.27K | ▲ +215.4% |
| 2002 | -0.07x | $-57.75K | $824.69K | ▲ +85.5% |
| 2001 | -0.48x | $-457.45K | $948.90K | ▼ -70.5% |
| 2000 | -0.28x | $-506.44K | $1.79 Million | ▼ -106.6% |
| 1999 | -0.14x | $-207.14K | $1.51 Million | ▲ +91.2% |
| 1998 | -1.56x | $-1.62 Million | $1.04 Million | ▼ -28.5% |
| 1997 | -1.22x | $-3.14 Million | $2.59 Million | ▼ -578.5% |
| 1996 | -0.18x | $-1.39 Million | $7.73 Million | — |